We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Digital Pathology System Provides Exceptional Image Quality Within Seconds

By LabMedica International staff writers
Posted on 02 Aug 2022
Print article
Image: OS-Ultra high-performance Digital Pathology System has received CE-IVDR mark (Photo courtesy of OptraSCAN)
Image: OS-Ultra high-performance Digital Pathology System has received CE-IVDR mark (Photo courtesy of OptraSCAN)

A high-performance digital pathology system that delivers exceptional image quality within seconds is setting new standards for laboratories.

OptraSCAN’s (Sunnyvale, CA, USA) high-performance OS-Ultra product line of brightfield scanners has a loading capacity of 80 to 480 slides. With no-touch continuous loading, it scans tissues or cells with a 15 mm x 15 mm area at 40x magnification in less than 60 seconds. They produce high-resolution images that can be analyzed further with the help of OptraSCAN's artificial intelligence-based software. This platform is capable of scanning histopathology and cytopathology slides. In addition, it can be configured with 5 to 11 layers for volume scanning or viewed as composite, single layer, fully focused image.

The tray and basket system used by OS-Ultra scanners are designed to efficiently transfer and position slides for scanning and prevent slide handling mistakes. For organizations seeking to scale up operations by increasing throughput, OS Ultra is an efficient, consistent, and accurate solution. OptraSCAN has received CE-IVDR marking for the OS-Ultra scanners, which are available at an extremely affordable price point, including pay-per-scan based OPEX models. OptraSCAN's full digital pathology solutions include scanning devices, image management and viewing software, telepathology software, and image analysis solutions for biomarker and morphometry.

"The CE-IVDR mark will enhance the acceptability of OS-Ultra systems across the globe and strengthen OptraSCAN's mission to improve patient outcomes with affordable and easy to implement digital pathology solutions," said Abhi Gholap, Founder CEO of OptraSCAN.

Related Links:
OptraSCAN 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more